Philippe A. Cassier

Centre National de la Recherche Scientifique

Also affiliated with Inserm, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study”.

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00247-3

N/A

5.0DataRank · unranked

445 citations

Giuseppe Curigliano, Dong‐Wan Kim, Ki Hyeong Lee, Benjamin Besse, Christina S. Baik +20 more

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Nature Medicine(2022)10.1038/s41591-022-01931-y

N/A

3.9DataRank · unranked

240 citations

Philippe A. Cassier, Salvatore Siena, Elena Garralda, Luis Paz‐Ares, Pilar Garrido +14 more

Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study

The Lancet. Gastroenterology & hepatology(2022)10.1016/s2468-1253(21)00382-4

N/A

2.2DataRank · unranked

73 citations

Philippe A. Cassier, Marwan Fakih, Steven Kao, Dorte Nielsen, Antoîne Italiano +17 more

Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study

International Journal of Cancer(2021)10.1002/ijc.33861

N/A

1.9DataRank · unranked

62 citations

Jean‐Yves Blay, Irene García, Johann S. De Bono, Christophe Le Tourneau, Víctor Moreno +25 more

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study

Thyroid(2023)10.1089/thy.2023.0363

N/A

1.2DataRank · unranked

55 citations

Mimi I. Hu, Aaron S. Mansfield, Matthew H. Taylor, Martin Schüler, Viola W. Zhu +19 more

Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.11.018

N/A

0.312DataRank · unranked

7 citations

Natraj Reddy Ammakkanavar, Antoine Hollebecque, Dae Ho Lee, Takafumi Koyama, Philippe A. Cassier +20 more

NF-κB subunits RelA and c-Rel selectively control CD4+ T cell function in multiple sclerosis and cancer

The Journal of Experimental Medicine(2024)10.1084/jem.20231348

N/A

0DataRank · unranked

17 citations

Raphaëlle Lautraite, Khaled Bouherrou, Maud Plaschka, Aurora Pignata, Allison Voisin +22 more